Low Remifentanil Target Controlled Infusions for Cardiac Surgery

• Status: Completed
• Trial end date: 2019-05-15
• Target enrollment: 0
• Participant gender: All

Summary

The development of target effect-site controlled concentrations (TCI) of remifentanil have gained increasing acceptance during cardiac surgery as regarding the resulting of hemodynamic stability and early extubation. The use of low-dose opioid technique has been progressively used nowadays because of its ceiling effect to attenuate cardiovascular responses to noxious stimuli. We hypothesize that the use of low target remifentanil effect site concentrations may provide comparable shorter times to tracheal extubation and hemodynamic stability to the use of high remifentanil Ce during target-controlled propofol anesthesia for cardiac surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dammam University
• Treatments: Remifentanil

Criteria

Inclusion Criteria:

• Older than 18 years

• American Society of Anesthesiologists class III and IV

• eligible for early extubation

Exclusion Criteria:

• uncontrolled hypertension

• ischemic heart disease

• left ventricular ejection fraction ≤45%

• mean pulmonary artery pressure ≥50 mm Hg

• critical aortic stenosis

• pulmonary diseases

• hepatic diseases

• renal diseases

• neuromuscular diseases

• neuropsychiatric diseases

• endocrine diseases

• body mass index ≥40 kg/m2

• pregnancy

• use of antipsychotics

• use of alcohol

• drug abuse

• repeat surgery

• emergency surgery

• those requiring preoperative circulatory support

• those whose electrocardiographic characteristics would interfere with ST-segment monitoring